This website is intended for UK healthcare professionals only Log in | Register

Editorial articles

October 2024 Br J Cardiol 2024;31(4) doi:10.5837/bjc.2024.042 Online First

Grüntzig’s technique, relearnt

Pitt O Lim

Abstract

A quiet revolution without fanfare took place at a meeting, witnessed by over 1,000 people both in London and live streamed across the globe on 31 January 2024. It was unprecedented, going against received wisdom. That, it was possible to treat atherosclerotic coronary artery disease with an updated Andreas Grüntzig’s balloon alone, without the safety net and comfort of implanting a single stent. Three interactive cases were treated with the drug-coated balloon and all patients were same-day discharged. Seemingly a show of simplicity, parsimony and bravado, but dive a little deeper, the skill set for stent-free coronary intervention has been meticulously studied over the last 20 years by pioneers and early adopters alike. The sacred cow slayed on this historic day was that balloon-inflicted coronary dissection rarely leads to occlusion, having effective antiplatelet therapy on board. And, potentially occlusive dissection is, not only predictable, but this method can be used in the ambulatory care setting. Thus, saving hospital bed stays. This event will be remembered as the tipping point at which a paradigm shift has occurred, but going back to embracing Grüntzig’s lessons. This is timely too, considering that two decades of systematic stenting has led to stent failures comprising nearly a third of daily interventional workload.

| Full text

September 2024 Br J Cardiol 2024;31:85–7 doi:10.5837/bjc.2024.039

Integrated working in cardiovascular care

Raj Thakkar

Abstract

There is little doubt that demand on the National Health Service (NHS) has exceeded supply. Given the rhetoric of no more money, no new workforce, and no new estates, it is incumbent on us all to make better and more efficient use of the limited resource we do have, improve how we work together as one integrated health, community and social care ecosystem, and increase the value of every action we take. Cardiovascular services are no exception.

| Full text

August 2024 Br J Cardiol 2024;31:88–91 doi:10.5837/bjc.2024.034

Mentorship for cardiology trainees: appealing or appalling?

Alysha Bhatti, Pok-Tin Tang, Michael Drozd, C Fielder Camm

Abstract

Training and development of cardiology trainees in the UK at a local level, is usually delivered through senior supervision by a consultant cardiologist. This training is overseen by clinical and educational supervisors, whose role is to set goals in line with existing training curricula. This is crucial to ensuring trainee development and attainment of skills in line with a pre-determined ‘gold standard’ for independent practice.

| Full text

July 2024 Br J Cardiol 2024;31:83–4 doi:10.5837/bjc.2024.027

Understanding the failings of yesterday to improve the outcomes of tomorrow: a cardiorenal story

Matthew P M Graham-Brown, James O Burton, Rupert W Major

Abstract

“In spite of the accumulating evidence of their efficacy, established treatments for maintaining renal function remain woefully underutilized. Clinicians and health care systems must be encouraged to make use of these treatments.”1

The above was written in an editorial by Thomas Hostetter1 that accompanied three landmark nephrology trials published in 2001.2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. These trials added weight to the evidence that supported the use of both angiotensin-converting enzyme inhibitors (ACEi) or ARBs in diabetic kidney disease and chronic kidney disease (CKD), particularly in patients with proteinuria.5 The evidence-base supporting the use of these drugs for patients with heart failure and cardiovascular diseases is unquestioned, and given the inter-related nature of the heart and the kidneys, the hope and optimism around these drugs was understandable. Dr Hostetter, however, was right to be cautious in his appraisal of the impact these medications might have on outcomes for patients with CKD, not because of the quality or compelling nature of the trial data, but because of the difficulties overcoming clinical and systems-related inertia to achieve effective implementation of the drugs. His predictions have proved cogent.

| Full text

May 2024 Br J Cardiol 2024;31:45–8 doi:10.5837/bjc.2024.019

Cardiac ejection fraction as a problematic metric for heart failure phenotyping

Rienzi A Diaz-Navarro, Peter L M Kerkhof

Abstract

“Seek simplicity and distrust it.”
Alfred North Whitehead (1861–1947), English philosopher and mathematician

The metric ejection fraction (EF) is widely employed to evaluate ventricular pumping performance, used for heart failure (HF) classification, and its calculation is simple.1–3 For example, with end-systolic volume (ESV) =50 ml and end-diastolic volume (EDV) =100 ml, the EF=50%. Unfortunately, its correct interpretation received insufficient attention. As EF is a ratio-based number (or percentage) without physical unit(s), it cannot provide unique information. The underlying problem, and also a logical solution, can be shown by the ventricular volume domain representation (figure 1A) that relates ESV to EDV. Volumes may be indexed (i) for body surface area, if appropriate. Focusing on ESVi and EDVi is important, as this combination is associated with the familiar pressure–volume (PV) loop description, which, in turn, connects with clinically relevant characteristics, such as stroke work and myocardial oxygen consumption (MVO2).1

| Full text

April 2024 Br J Cardiol 2024;31:43–4 doi:10.5837/bjc.2024.013

The impact of air pollution on atherosclerotic cardiovascular disease development

Clayton Tewma, Justin Lee Mifsud

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide, causing around 17.9 million deaths annually, a third of whom are adults aged <70 years.1 In addition to genetic and behavioural risk factors (unhealthy diet, physical inactivity, and tobacco and alcohol abuse), inhaling airborne pollutants, such as fine particulate matter (<2.5 µm [PM2.5] and <10 µm [PM10]), ultrafine particles (UFPs; <100 nm), nitrogen dioxide (NO2), ozone (O3), and sulphur dioxide (SO2), are associated with ASCVD among adults.2

Air pollution has been referred to as “the single most important environmental factor presenting a risk to health and represents a greater disease burden than polluted water, soil contamination and occupational exposures combined”.3 Air pollution is a silent killer and was highlighted as a significant public health concern in the recently published European Society of Cardiology (ESC) guidelines.4

The impact of urbanisation on air pollution levels is a critical concern for countries like Malta, which have adopted a city model to bolster their economies. Despite efforts to stimulate economic growth, the rise in urbanisation can pose risks to air quality. In London, mean PM2.5 concentrations stood at approximately 12.7 µg/m³ in 2017, 12.0 µg/m³ in 2018, and 11.4 µg/m³ in 2019.5 Conversely, Valletta, Malta’s capital, recorded mean PM2.5 concentrations of about 14 µg/m³ in 2017, 14.4 µg/m³ in 2018, and 14 µg/m³ in 2019.6 While both have seen improvements in their aggregated annual mean PM2.5 concentrations compared with the concentration levels recorded in the past decade, they still exceed the World Health Organisation (WHO) annual air quality guideline value by approximately 1.14 to 1.4 times, highlighting the persistent challenge of air pollution in urban environments.

| Full text

February 2024 Br J Cardiol 2024;31:7–8 doi:10.5837/bjc.2024.005

Rewriting the heart failure pillars toward less burdensome heart failure care pathways

Rosalynn C Austin

Abstract

At the Association of Cardiovascular Nursing & Allied Professions conference in June, Professor Tiny Jaarsma called for a pillar of self-care to be added to heart failure (HF) care guidelines.1 Taylor et al.2 agree that HF care needs an additional pillar and suggest cardiac rehabilitation. Currently, the HF pillars are focused on medications shown to improve the outcomes of people with heart failure with reduced ejection fraction (HFrEF),3 but other key non-pharmacological interventions are not considered. Also, the pillars of care do not provide guidance for people with heart failure with preserved ejection fraction (HFpEF), which represent 50% of the HF population.4 While these pillars focus on a single important aspect of care, they do not capture the totality of HF management or illness types. A focus on interventions to improve HF management is welcome but can obscure the challenges that treatment – as well as illness – impose on patients and their carers.

| Full text

January 2024 Br J Cardiol 2024;31:4–6 doi:10.5837/bjc.2024.001

Dishing out the meds

David Mulcahy, Palwasha Khan

Abstract

Twenty years ago, Wald and Law1 hypothesised that, if a combination pill could be made including aspirin, folic acid, a statin, and a low-dose diuretic, beta blocker and angiotensin-converting enzyme (ACE) inhibitor (thus, allowing for the simultaneous modification of four different risk factors: low-density lipoprotein [LDL]-cholesterol, blood pressure, homocysteine, and platelet function), and administered to everyone with existing cardiovascular disease and everyone over 55 years old, there would be an 88% reduction in ischaemic heart disease events, and an 80% reduction in stroke. One third of people over the age of 55 years would benefit by gaining an average of 11 years free from a cardiac event or stroke (subsequently termed the vaccination approach). They called this pill the ‘Polypill’, and concluded that treatment would be acceptably safe and, with widespread use, would have a greater impact on the prevention of disease in the Western world than any other single intervention. They noted that, while such a preventative strategy was radical, if such a formulation existed that prevented cancer and was safe, it would be widely used. “It is time to discard the view that risk factors need to be measured and treated individually if found to be abnormal. There is much to gain and little to lose by the widespread use of these drugs.” While subsequent works have shown that folic acid is not prognostically beneficial in preventing cardiovascular disease,2 and that aspirin may not be beneficial overall in primary prevention settings,3 the concept of the combination pill was awakened in the public eye.

| Full text

November 2023 Br J Cardiol 2023;30:123–4 doi:10.5837/bjc.2023.036

Future-proofing UK echocardiography

Claire L Colebourn

Abstract

It is no secret that the National Health Service (NHS) is currently screaming along in fifth gear just to stay on a country lane: and we haven’t yet reached the motorway that lies ahead.

The NHS long-term plan couldn’t be more current, but it could perhaps have been more timely.1 Successive governments have watched our population changing shape and ageing over the last 20 years, but a powerful response to that looming ‘motorway’ of healthcare demand has only now materialised. The backlash of COVID-19 and the realisation of the impact of Brexit on NHS staff has become the ‘speed camera’ the NHS needed.

In 2022, the British Society of Echocardiography (BSE) commissioned Professor Alison Leary, Chair of Workforce Modelling at London South Bank University, to design a workforce survey that would allow us to fully understand the challenges facing the echocardiography workforce. This report and the policy report, which models solutions onto these data, can be read in full through our website (bsecho.org).2,3

This is my viewpoint on the messages contained within these gold-dust documents painted within the landscape of three years of fascinating conversations with many members of our profession and the national agencies we interact with.

| Full text

August 2023 Br J Cardiol 2023;30:83–5 doi:10.5837/bjc.2023.023

The delusion of measuring blood pressure

Gloria Hong, Breanna Hansen, Martha Gulati

Abstract

Hypertension affects over a billion people worldwide and is a leading cause of premature death and disability. However, it continues to remain a silent epidemic, with the majority of patients undiagnosed or untreated. The World Health Organisation reports that only 42% of individuals with hypertension receive a diagnosis and appropriate treatment. Furthermore, only one in five adults have their blood pressure under control.1 These statistics reflect a grave failure in identifying and managing a condition that has far-reaching health consequences. The misdiagnosis and undertreatment of blood pressure pose substantial risks to individuals and impose a tremendous burden on healthcare systems worldwide.

| Full text




Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now